| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Department of Cellular and Molecular Physiology, Tufts University School of Medicine, Boston, Massachusetts 02111
Often those diseases most evasive to therapeutic intervention usurp the human body's own cellular machinery or deregulate normal physiological processes for propagation. Tumor-induced angiogenesis is a pathological condition that results from aberrant deployment of normal angiogenesis, an essential process in which the vascular tree is remodeled by the growth of new capillaries from preexisting vessels. Normal angiogenesis ensures that developing or healing tissues receive an adequate supply of nutrients. Within the confines of a tumor, the availability of nutrients is limited by competition among actively proliferating cells, and diffusion of metabolites is impeded by high interstitial pressure (Jain RK. Cancer Res 47: 3039-3051, 1987). As a result, tumor cells induce the formation of a new blood supply from the preexisting vasculature, and this affords tumor cells the ability to survive and propagate in a hostile environment. Because both normal and tumor-induced neovascularization fulfill the essential role of satisfying the metabolic demands of a tissue, the mechanisms by which cancer cells stimulate pathological neovascularization mimic those utilized by normal cells to foster physiological angiogenesis. This review investigates mechanisms of tumor-induced angiogenesis. The strategies used by cancer cells to develop their own blood supply are discussed in relation to those employed by normal cells during physiological angiogenesis. With an understanding of blood vessel growth in both normal and abnormal settings, we are better suited to design effective therapeutics for cancer.
blood vessel; growth; cancer; endothelium; pericyte
This article has been cited by other articles:
|
|
 |
|
  A. Dimberg, S. Rylova, L. C. Dieterich, A.-K. Olsson, P. Schiller, C. Wikner, S. Bohman, J. Botling, A. Lukinius, E. F. Wawrousek, et al. {alpha}B-crystallin promotes tumor angiogenesis by increasing vascular survival during tube morphogenesis Blood, February 15, 2008; 111(4): 2015 - 2023. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Mottet, A. Bellahcene, S. Pirotte, D. Waltregny, C. Deroanne, V. Lamour, R. Lidereau, and V. Castronovo Histone Deacetylase 7 Silencing Alters Endothelial Cell Migration, a Key Step in Angiogenesis Circ. Res., December 7, 2007; 101(12): 1237 - 1246. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Michaud-Levesque, M. Demeule, and R. Beliveau In vivo inhibition of angiogenesis by a soluble form of melanotransferrin Carcinogenesis, February 1, 2007; 28(2): 280 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Muruganandham, M. Lupu, J. P. Dyke, C. Matei, M. Linn, K. Packman, K. Kolinsky, B. Higgins, and J. A. Koutcher Preclinical evaluation of tumor microvascular response to a novel antiangiogenic/antitumor agent RO0281501 by dynamic contrast-enhanced MRI at 1.5 T. Mol. Cancer Ther., August 1, 2006; 5(8): 1950 - 1957. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.W. Laschke, A. Elitzsch, B. Vollmar, P. Vajkoczy, and M.D. Menger Combined inhibition of vascular endothelial growth factor (VEGF), fibroblast growth factor and platelet-derived growth factor, but not inhibition of VEGF alone, effectively suppresses angiogenesis and vessel maturation in endometriotic lesions Hum. Reprod., January 1, 2006; 21(1): 262 - 268. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Y. Shin, W. K.K. Wu, K.-M. Chu, H. P.S. Wong, E. K.Y. Lam, E. K.K. Tai, M. W.L. Koo, and C.-H. Cho Nicotine Induces Cyclooxygenase-2 and Vascular Endothelial Growth Factor Receptor-2 in Association with Tumor-Associated Invasion and Angiogenesis in Gastric Cancer Mol. Cancer Res., November 1, 2005; 3(11): 607 - 615. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ansiaux, C. Baudelet, B. F. Jordan, N. Beghein, P. Sonveaux, J. De Wever, P. Martinive, V. Gregoire, O. Feron, and B. Gallez Thalidomide Radiosensitizes Tumors through Early Changes in the Tumor Microenvironment Clin. Cancer Res., January 15, 2005; 11(2): 743 - 750. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Streubel, A. Chott, D. Huber, M. Exner, U. Jager, O. Wagner, and I. Schwarzinger Lymphoma-Specific Genetic Aberrations in Microvascular Endothelial Cells in B-Cell Lymphomas N. Engl. J. Med., July 15, 2004; 351(3): 250 - 259. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Mycielska and M. B. A. Djamgoz Cellular mechanisms of direct-current electric field effects: galvanotaxis and metastatic disease J. Cell Sci., May 1, 2004; 117(9): 1631 - 1639. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Castilla, F. Neria, G. Renedo, D. S. Pereira, F. R. Gonzalez-Pacheco, S. Jimenez, P. Tramon, J. J. P. Deudero, M. V. A. Arroyo, S. Yague, et al. Tumor-induced endothelial cell activation: role of vascular endothelial growth factor Am J Physiol Cell Physiol, May 1, 2004; 286(5): C1170 - C1176. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. C. Hughes, S. S. Biswas, B. Yin, R. E. Coleman, T. R. DeGrado, C. K Landolfo, J. E. Lowe, B. H. Annex, and K. P. Landolfo Therapeutic angiogenesis in chronically ischemic porcine myocardium: comparative effects of bFGF and VEGF Ann. Thorac. Surg., March 1, 2004; 77(3): 812 - 818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. J. Hausman and R. L. Richardson Adipose tissue angiogenesis J Anim Sci, March 1, 2004; 82(3): 925 - 934. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zhang, N. Yang, J.-W. Park, D. Katsaros, S. Fracchioli, G. Cao, A. O'Brien-Jenkins, T. C. Randall, S. C. Rubin, and G. Coukos Tumor-derived Vascular Endothelial Growth Factor Up-Regulates Angiopoietin-2 in Host Endothelium and Destabilizes Host Vasculature, Supporting Angiogenesis in Ovarian Cancer Cancer Res., June 15, 2003; 63(12): 3403 - 3412. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Wachsberger, R. Burd, and A. P. Dicker Tumor Response to Ionizing Radiation Combined with Antiangiogenesis or Vascular Targeting Agents: Exploring Mechanisms of Interaction Clin. Cancer Res., June 1, 2003; 9(6): 1957 - 1971. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. C. Hughes, M. J. Post, M. Simons, and B. H. Annex Translational Physiology: Porcine models of human coronary artery disease: implications for preclinical trials of therapeutic angiogenesis J Appl Physiol, May 1, 2003; 94(5): 1689 - 1701. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Takahashi, K. Takahashi, P. L. St. John, P. A. Fleming, T. Tomemori, T. Watanabe, D. R. Abrahamson, C. J. Drake, T. Shirasawa, and T. O. Daniel A Mutant Receptor Tyrosine Phosphatase, CD148, Causes Defects in Vascular Development Mol. Cell. Biol., March 1, 2003; 23(5): 1817 - 1831. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Zhang, N. Yang, J.-R. Conejo Garcia, A. Mohamed, F. Benencia, S. C. Rubin, D. Allman, and G. Coukos Generation of a Syngeneic Mouse Model to Study the Effects of Vascular Endothelial Growth Factor in Ovarian Carcinoma Am. J. Pathol., December 1, 2002; 161(6): 2295 - 2309. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
